14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IONS vs INCY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas INCY carries 61.2/100 (BUY) at $119.86 (14.0x Forward P/E, 32.2% operating margin).
Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. INCY 61.2/100 BUY), INCY captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (32.2% vs. -58.8% operating margin) and revenue trajectory (+14.0% vs. +54.9% YoY).
Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile INCY trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 52.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment61.8% of Rev ($593M)
90D Engineering Disclosures0 Published
INCY Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $24.8B market capitalization and 32.2% operating margin.
OpEx & R&D Reinvestment23.8% of Rev ($1.43B)
90D Engineering Disclosures0 Published
Investor FAQ IONS vs INCY Key Questions & Quantitative Answers
As of Nov 16, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas INCY carries 61.2/100 (BUY) at $119.86 (14.0x Forward P/E, 32.2% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. INCY 61.2/100 BUY), INCY captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (32.2% vs. -58.8% operating margin) and revenue trajectory (+14.0% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile INCY trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 52.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
INCY leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with INCY at +14.0% YoY revenue growth and +37.7% YoY earnings growth on $6.01B TTM revenue (56.0% gross margin, 32.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IONS cumulative revenue shifted +56.7% while INCY shifted +173.4%. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 23.8% of Rev ($1.43B) (0 disclosures) for INCY.
INCY screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas INCY trades at 14.0x Forward P/E, 62.1x Trailing P/E, 10.82x PEG, and 3.6x EV/Revenue (11.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus INCY (7.8% ROE) capital efficiency.
In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, INCY carries 36.5% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 35% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.